App-Quantinova.ai

A retrospective review of venous thrombosis in 16‐18 year old patients in a tertiary referral centre over a 5 year period (2013 – 2017)

G. Swallow - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Enoxaparin

Prognostic value of clone size in paroxysmal nocturnal hemoglobinuria (PNH) for thrombotic events in untreated patients in the International PNH Registry

R. Peffault De Latour - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Prevalence of small PNH clones and their prognostic significance in patients tested for unusual indications: a single center experience

B. Fattizzo - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Moyamoya syndrome in a patient with alpha thalassaemia

S. Khairullah - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Acetazolamide Sodium

A Survey of UK Myeloma treating centres on thrombosis risk assessment and thromboprophylaxis practice in patients with Multiple Myeloma

R. Oliver - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

apixaban

Warfarin is well absorbed from gastric mucosa alone in patients with extensive bowel resection: A case report of a patient with ultrashort bowel syndrome following portal and superior mesenteric vein thrombosis and antiphospholipid syndrome

M. Khakwani - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Warfarin

Use of antithrombin concentrate in acquired antithrombin deficiency in acutely unwell children receiving unfractionated heparin – a single centre experience

D. Jayakody Arachchillage - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Incidences of thrombosis, major bleeding and 30‐day mortality in patients receiving veno‐venous extracorporeal membrane oxygenation and value of laboratory parameters at presentation in predicting outcomes

D. Jayakody Arachchillage - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Fibrinogen (IV)

Single centre audit of testing F8 genetics and identifying the p.Tyr365Cys mutation in mild haemophilia A: implications for patient care and resources

R. Chengal - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Tranexamic acid

Venous thromboembolism and race: A systematic review and meta‐analysis

K. Butterworth - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Can long acting factors go a long way; a real‐life single centre retrospective study of Haemophilia B patients who have switched to extended half‐life factor IX

A. Rampotas - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Alprolix Intravenous

Apixaban plasma levels in obese patients

V. Ware - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

apixaban

Extensive screening for occult malignancy in all unprovoked venous thromboembolism above 40 years old: Are we overdoing it?

C.L. Neoh - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Methadone hydrochloride

A clinical decision support system allows real‐time monitoring of compliance to hospital transfusion guidelines and immediate education regarding inappropriate inpatient transfusions

A. King - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Acute Promyelocytic Leukaemia Presenting as Acute Myocardial Infarction

B. Salhan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Fibrinogen (IV)

The impact of the BSH 2018 polycythaemia vera guidelines on clinical management in the Sheffield and Barnsley catchment area

S. Francis - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Hydroxycarbamide

Life‐threatening Hypereosinophilic Syndrome in a 7 year old child

Y.L.T. Chan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Methylprednisolone

Improving Adherence to NICE Guidelines for Investigation of Malignancy in Unprovoked DVT: A Single Centre Experience

E. Millen - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Dabigatran overdose requiring multiple doses of idaricuzimab; clinical and laboratory features

L. Nelmes - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Idarucizumab

A Novel Approach for Improving Compliance with Venous Thromboembolism (VTE) Risk Reassessment in Patients Undergoing Endoscopy for Acute Gastrointestinal (GI) Bleed

R. Hargreaves - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Filters

7277 Abstracts